Adducin polymorphisms and the treatment of hypertension

Pharmacogenomics

Volumn 8, Issue 5, 2007, Pages 465-472

  Manunta, Paolo ^a   Citterio, Lorena ^a   Lanzani, Chiara ^a   Ferrandi, Mara ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Prassis Sigma Tau Research Institute   (Italy)

Author keywords

Blood pressure; Digitalis like factor; Genetic; Na pump; Renal

Indexed keywords

ADDUCIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; CYTOSKELETON PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCINE; HYDROCHLOROTHIAZIDE; OUABAIN; RENIN; ROSTAFUROXIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE MODEL; DRUG USE; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; ESSENTIAL HYPERTENSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE PHENOTYPE CORRELATION; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY TUBULE ABSORPTION; MIGRATION; MULTIGENE FAMILY; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PATIENT SELECTION; PHARMACOGENETICS; PHARMACOGENOMICS; PUBLIC HEALTH PROBLEM; REVIEW; SALT INTAKE; SODIUM ABSORPTION; STROKE; TREATMENT OUTCOME; UNITED STATES;

ANIMALS; CALMODULIN-BINDING PROTEINS; DIURETICS; HUMANS; HYPERTENSION; MULTIGENE FAMILY; OUABAIN; POLYMORPHISM, GENETIC;

ANIMALIA; RATTUS;

EID: 34248569586     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.5.465     Document Type: Review

References (62)

1. Chobanian AV, Bakris GL, Black HR et al.; National High Blood Pressure Education Program Coordinating Committee: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension 42 1206-1252 (2003).
2. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet 362, 1527-1535 (2003).
3. Bianchi G: Genetic variations of tubular sodium reabsorption leading to 'primary' hypertension: from gene polymorphism to clinical symptoms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289, R1536-R1549 (2005).
4. Matsuoka Y, Li X, Bennett V: Adducin: structure, function and regulation. Cell. Mol. Life Sci. 57, 884-895 (2000).
5. Hughes CA, Bennett V: Adducin: a physical model with implications for function in assembly of spectrin-actin complexes. J. Biol. Chem. 270, 18990-18996 (1995).
6. Kuhlman PA, Hughes CA, Bennett V, Fowler VM: A new function for adducin: calcium/calmodulin-regulated capping of the barbed ends of actin filaments. J. Biol. Chem. 271, 7986-7991 (1996).
7. 2+-dependent association with sites of cell-cell contact. J. Cell Biol. 109, 557-569 (1989).
8. Gotoh H, Okumura N, Yagi T, Okumura A, Shima T, Nagai K: Fyn-induced phosphorylation of β-adducin at Tyr 489 and its role in their subcellular localization. Biochem. Biophys. Res. Commun. 346, 600-605 (2006).
9. Pariser H, Perez-Pinera P, Ezquerra L, Herradon G, Deuel TF: Pleiotrophin stimulates tyrosine phosphorylation of β-adducin through inactivation of the transmembrane receptor protein tyrosine phosphatase β/ζ. Biochem. Biophys. Res. Commun. 335, 232-239 (2005).
10. Matsuoka Y, Li X, Bennett V: Adducin is an in vivo substrate for protein kinase C: phosphorylation in the MARCKS-related domain inhibits activity in promoting spectrin-actin complexes and occurs in many cells, including dendritic spines of neurons: J. Cell Biol. 142, 485-497 (1998).
11. Aderem A: The MARCKS brothers: a family of protein kinase C substrates. Cell 71, 713-716 (1992).
12. Fukata Y, Oshiro, N, Kinoshita N et al.: Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility: J. Cell Biol. 145, 347-361 (1999).
13. Lu Q, Liu X, Trama J, Roti MA, Go WY, Ho SN: Identification of the cytoskeletal regulatory protein α-adducin as a target of T cell receptor signalling. Mol. Immunol. 41, 435-447 (2004).
14. Lin B, Nasir J, McDonald H et al.: Genomic organization of the human α-adducin gene and its alternatively spliced isoforms. Genomics 25, 93-99 (1995).
15. Gilligan DM, Lozovatsky L, Silberfein A: Organization of the human β-adducin gene (ADD2). Genomics 43, 141-148 (1997).
16. Citterio, L, Tizzoni L, Catalano M, Zerbini G, Bianchi G, Barlassina C: Expression analysis of the human adducin gene family and evidence of ADD2 β4 splicing variants. Biochem. Biophys. Res. Commun. 309, 359-367 (2003).
17. Sinard JH, Stewart GW, Stabach PR et al.: Utilization of an 86 bp exon generates a novel adducin isoform (β4) lacking the MARCKS homology domain. Biochim. Biphys. Acta 1396, 57-66 (1998).
18. Citterio L, Azzani T, Duga S, Bianchi G: Genomic organization of the human γ-adducin gene. Biochem. Biophys. Res. Commun. 266, 110-114 (1999).
19. Costessi L, Devescovi G, Baralle FE, Muro AF: Brain-specific promoter and polyadenylation sites of the β-adducin pre-mRNA generate an unusually long 3′-UTR. Nudeic Acids Res. 34(1), 243-253 (2006).
20. Cusi D, Barlassina C, Azzani T et al.: Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 349, 1353-1357 (1997).
21. Tripodi G, Valtorta F, Torielli L et al.: Hypertension-associated point mutations in the adducin α and β subunits affect actin cytoskeleton and ion transport. J. Clin. Invest. 97(12), 2815-2822 (1996).
22. Ferrandi M, Salardi S, Tripodi G et al.: Evidence for an interaction between adducin and Na, K-ATPase: relation to genetic hypertension. Am. J. Physiol. 277, 1338-1349 (1999).
23. Torielli L, Padoani G, Tarsini P: Adducin may affect the residential time of the Na-K pump on the plasma membrane. Eur. J. Cell Blol. 79(Suppl. 52), 164 (2000).
24. Efendiev R, Krmar RT, Ogimoto G et al.: Hypertension-linked mutation in the adducin α-subunit leads to higher AP2-μ2 phosphorylation and impaired Na, K-ATPase trafficking in response to GPCR signals and intracellular sodium. Circ. Res. 95, 1100-1108 (2004).
25. Xie Z, Askari A: Na-K ATPase as a signal transducer. Eur. J. Biochem. 269(10), 2434-2439 (2002).
26. Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, Ferrari P: Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. J. Biol. Chem. 279(32), 33306-33314 (2004).
27. Anderson RG, Jacobson K: A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 296(5574), 1821-1825 (2002).
28. Ferrandi M, Molinari I, Ferrari P, Giuseppe B: Hypertension-related adducin polymorphism activates signal transduction pathways via Na-K ATPase within renal caveolae in a congentc rat model. 59th Annual Meeting of the Society of General Physiologists. Woods Hole, MA, USA, September 6-11, 2005 (Abstract 169).
29. Glorioso N, Filigheddu F, Cusi D et al.: α-adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. Hypetension 39, 357-362 (2002).
30. Staessen JA, Wang JG, Brand E et al.: Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J. Hypertens. 19, 1349-1358 (2001).
31. Manunta P, Burnier M, D'Amico M et al.: Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. Hypertension 33(2), 694-697 (1999).
32. Barlassina C, Schork NJ, Manuta P et al.: Synergistic effect of α-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney Intern. 57, 1083-1090 (2000).
33. Sugimoto K, Hozawa A, Katsuya T et al.: α-adducin Gly460Trp polymorphism is associated with low renin hypertension in younger subjects in the Ohasama study. J. Hypertens. 20, 1779-1784 (2002).
34. Winnicki M, Somers VK, Accurso V et al.; HARVEST Study Group: α-adducin Gly460Trp polymorphism, left ventricular mass and plasma rennin activity. J. Hypertens. 20, 1771-1777 (2002).
35. 2 receptor and α-adducin gene polymorphisms. J. Clin. Endocrinol. Metab. 87, 3337-3343 (2002).
36. Lanzani C, Citterio, L, Jankaricova M et al.: Role of the adducin family genes in human essential hypertension. J. Hypertens. 23(3), 543-549 (2005).
37. Cwynar M, Staessen JA, Ticha M et al.: Epistatic interaction between α and γ-adducin influences peripheral and central pulse pressure in white Europeans: J. Hypertens. 23, 961-969 (2005).
38. Li Y, Thijs L, Kuznetsova T et al.: Cardiovascular risk in relation to α-adducin Gly460Trp polymorphism and systolic pressure: a prospective population study. Hypertension 46(3), 527-532 (2005).
39. Psaty BM, Smith NL, Heckbert SR et al.: Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 287, 1680-1689 (2002).
40. Glorioso N, Manunta P, Filigheddu F et al.: The rule of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 34, 649-654 (1999).
41. Sciarrone MT, Stella P, Barlassina C et al.: ACE and α-adducin polymorphisms as markers of individual response to diuretic therapy. Hypertension 41, 398-403 (2003).
42. Swart S, Bing RF, Swales JD, Thurston H: Plasma renin in long-term diuretic treatment of hypertensive: effect of discontinuation and restarting therapy. Clin. Sci. 63, 121-125 (1982).
43. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E: Effects of endothelial nitric oxide synthase, α-Adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am. J. Hypertens. 16, 834-839 (2003).
44. Meckley LM, Veenstra DL: Screening for the α-Adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet. Genomics 16(2), 139-147 (2006).
45. Verdecchia P, Angeli F, Reboldi GP, Gattobigio R: New onset diabetes in treated hypertensive patients. Curr. Hypertens. Rep. 7, 174-179 (2005).
46. Arnett DK, Davis BR, Ford CE et al.: Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111(25), 3374-3383 (2005).
47. Davis BR, Arnett DK, Boerwinkie E et al.: Antihypertensive therapy, the α-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. Pharmacogenomics J. 7(2), 112-122 (2007).
48. Aydemir-Koksoy A, Abramowitz J, Allen JC: Ouabain induced signaling and wascular smooth muscle cell proliferation. J. Biol. Chem. 276, 46605-46611 (2001).
49. Dostanic I, Paul RJ, Lorenz JN, Theriault S, van Huysse JW, Lingrel JB: The α2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am. J. Physiol. Heart Circ. Physiol. 288(2), H477-H485 (2005).
50. Pierdomenico SD, Bucci A, Manunta P et al.: Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. Am. J. Hypertens. 14(1), 44-50 (2001).
51. Manunta P, Stella P, Rivera R et al.: Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Hypertension 34(3), 450-456 (1999).
52. +-ATPase alterations in ouabain and Adducin-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290(3), R529-R535 (2006).
53. Huang L, Li H, Xie Z: Ouabain-induced hypertrophy in cultured cardiac myocytes is accompanied by changes in expression of several late response genes. J. Moll. Cell. Cardiol. 29, 429-437 (1997).
54. Scheiner-Bobis G, Schoner W: A fresh facet for ouabain action. Nat. Med. 7, 1288-1289 (2001).
55. Godfraind T, Ghysel-Burton J: Binding sites related to ouabain-induced stimulation or inhibition of the sodium pump. Nature 265, 165-166 (1977)
56. Zhang J, Lee MY, Cavalli M et al.: Sodium pump α2 subunits control myogenic tone and blood pressure in mice. J. Physiol. 56, 243-256 (2005).
57. Manunta P, Iacoviello M, Forleo C et al.: High circulating levels of endogenous ouabain in the offspring of hypertensive and normotensive individuals. J. Hypertens. 23(9), 1677-1681 (2005).
58. Manunta P, Messaggio, E, Ballabeni C et al.: Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 38(2), 198-203 (2001).
59. Pitzalis MV, Hamlyn JM, Messaggio E et al.: Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. Eur. J. Heart Fail. 8(2), 179-186 (2006).
60. Lopatin DA, Ailamazian EK, Dmitrieva RI: Circulating bufodienolide and cardenolide sodium pump inhibitors in pre-eclampsia. J. Hypertens. 17(8), 1179-1187 (1999).
61. Balzan S, Neglia D, Ghione S: Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. Eur. J. Heart Fail. 3(2), 165-171 (2001).
62. Staessen JA, Kuznetsova T, Acceto R et al.: OASIS-HT: design of a pharmacogenomic dose-finding study. Pharmacogenomics 6(7), 755-775 (2005).